Moderna starts late-stage trial for bird flu shot (MRNA)
Summary
Moderna stock gains as the company begins dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu vaccine candidate, mRNA-1018. Read mor...
Description
Moderna stock gains as the company begins dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu vaccine candidate, mRNA-1018. Read mor...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source